452 related articles for article (PubMed ID: 31653695)
1. Impaired tau-microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations.
Xia Y; Sorrentino ZA; Kim JD; Strang KH; Riffe CJ; Giasson BI
J Biol Chem; 2019 Nov; 294(48):18488-18503. PubMed ID: 31653695
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic MAPT mutations Q336H and Q336R have isoform-dependent differences in aggregation propensity and microtubule dysfunction.
Xia Y; Nasif L; Giasson BI
J Neurochem; 2021 Jul; 158(2):455-466. PubMed ID: 33772783
[TBL] [Abstract][Full Text] [Related]
3. Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
Strang KH; Croft CL; Sorrentino ZA; Chakrabarty P; Golde TE; Giasson BI
J Biol Chem; 2018 Feb; 293(7):2408-2421. PubMed ID: 29259137
[TBL] [Abstract][Full Text] [Related]
4. A novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function.
Iyer A; Lapointe NE; Zielke K; Berdynski M; Guzman E; Barczak A; Chodakowska-Żebrowska M; Barcikowska M; Feinstein S; Zekanowski C
PLoS One; 2013; 8(9):e76409. PubMed ID: 24086739
[TBL] [Abstract][Full Text] [Related]
5. MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Strang KH; Golde TE; Giasson BI
Lab Invest; 2019 Jul; 99(7):912-928. PubMed ID: 30742061
[TBL] [Abstract][Full Text] [Related]
6. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
Stancu IC; Ferraiolo M; Terwel D; Dewachter I
Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
[TBL] [Abstract][Full Text] [Related]
7. Tau Lysine Pseudomethylation Regulates Microtubule Binding and Enhances Prion-like Tau Aggregation.
Xia Y; Bell BM; Giasson BI
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175990
[TBL] [Abstract][Full Text] [Related]
8. Cellular and pathological heterogeneity of primary tauopathies.
Chung DC; Roemer S; Petrucelli L; Dickson DW
Mol Neurodegener; 2021 Aug; 16(1):57. PubMed ID: 34425874
[TBL] [Abstract][Full Text] [Related]
9. P301 L, an FTDP-17 Mutant, Exhibits Enhanced Glycation in vitro.
Sonawane SK; Chinnathambi S
J Alzheimers Dis; 2020; 75(1):61-71. PubMed ID: 32250308
[TBL] [Abstract][Full Text] [Related]
10.
Ingham DJ; Hillyer KM; McGuire MJ; Gamblin TC
Biochemistry; 2022 Jul; 61(13):1243-1259. PubMed ID: 35731895
[TBL] [Abstract][Full Text] [Related]
11. Amyloidogenesis of Tau protein.
Nizynski B; Dzwolak W; Nieznanski K
Protein Sci; 2017 Nov; 26(11):2126-2150. PubMed ID: 28833749
[TBL] [Abstract][Full Text] [Related]
12. Tau isoform-specific stabilization of intermediate states during microtubule assembly and disassembly.
Best RL; LaPointe NE; Liang J; Ruan K; Shade MF; Wilson L; Feinstein SC
J Biol Chem; 2019 Aug; 294(33):12265-12280. PubMed ID: 31266806
[TBL] [Abstract][Full Text] [Related]
13. Tau alternative splicing in familial and sporadic tauopathies.
Niblock M; Gallo JM
Biochem Soc Trans; 2012 Aug; 40(4):677-80. PubMed ID: 22817715
[TBL] [Abstract][Full Text] [Related]
14. Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies.
Karch CM; Jeng AT; Goate AM
J Biol Chem; 2012 Dec; 287(51):42751-62. PubMed ID: 23105105
[TBL] [Abstract][Full Text] [Related]
15. FTDP-17 tau mutations induce distinct effects on aggregation and microtubule interactions.
Combs B; Gamblin TC
Biochemistry; 2012 Oct; 51(43):8597-607. PubMed ID: 23043292
[TBL] [Abstract][Full Text] [Related]
16. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
17. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
[TBL] [Abstract][Full Text] [Related]
18. Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies.
Silva MC; Haggarty SJ
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255694
[TBL] [Abstract][Full Text] [Related]
19. Genetic forms of tauopathies: inherited causes and implications of Alzheimer's disease-like TAU pathology in primary and secondary tauopathies.
Langerscheidt F; Wied T; Al Kabbani MA; van Eimeren T; Wunderlich G; Zempel H
J Neurol; 2024 Jun; 271(6):2992-3018. PubMed ID: 38554150
[TBL] [Abstract][Full Text] [Related]
20. The role of tau (MAPT) in frontotemporal dementia and related tauopathies.
Rademakers R; Cruts M; van Broeckhoven C
Hum Mutat; 2004 Oct; 24(4):277-95. PubMed ID: 15365985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
